赛洛西宾与慢性神经病理性疼痛:一项系统综述
该系统综述检索至2024年1月的多个数据库,纳入28项评估赛洛西宾治疗慢性疼痛的研究,多数证据质量低或极低,部分中低质量证据采用0.14 mg/kg方案,提示赛洛西宾可能缓解慢性疼痛但需更高质量研究。
要点
- 赛洛西宾在慢性疼痛缓解中显示潜力,但现有证据质量普遍较低。
- 76.2%的纳入研究为低或极低质量,方法学问题突出。
- 部分中低质量证据研究采用0.14 mg/kg剂量方案。
核心结论
- 当前研究表明赛洛西宾作为慢性疼痛缓解治疗选择具有潜力,但方法学问题及缺乏高质量证据,需标准化方案的进一步研究。
研究设计与样本
- 系统综述检索PubMed、CINAHL、Web of Science、Cochrane Library和EMBASE至2024年1月,纳入评估赛洛西宾用于慢性疼痛管理的研究,使用MASTER量表评估偏倚风险,GRADE分级证据强度。
主要发现
- 共纳入28项相关研究,关注给药方案、治疗病症和结局。
- 76.2%的纳入研究为低或极低质量。
- 部分中低质量证据研究采用0.14 mg/kg剂量方案。
- 研究结果提示赛洛西宾在慢性疼痛缓解中有前景,但证据质量普遍较低。
临床怎么用
- 赛洛西宾在慢性疼痛管理中显示潜力,但当前证据质量低,临床决策需谨慎,不应常规推荐。
局限性
- 多数纳入研究为低或极低质量,方法学问题突出。
- 缺乏高质量证据和标准化方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/IMPORTANCE: Chronic pain affects many people globally, requiring alternative management strategies. Psilocybin is gaining attention for its potential in chronic pain management despite being classified as Schedule I. OBJECTIVE: This systematic review critically evaluates the evidence for psilocybin, a Schedule I substance, in the treatment of chronic pain. The exact purpose of the review is to assess the impact of psilocybin on chronic pain relief, focusing on dosing protocols, treated conditions, and patient outcomes. EVIDENCE REVIEW: A comprehensive review of PubMed, CINAHL, Web of Science, Cochrane Library, and EMBASE was conducted up to January 2024. Eligibility criteria included studies evaluating psilocybin for chronic pain management. The risk of bias was assessed using the MASTER (MethodologicAl STandards for Epidemiological Research) scale, and the strength of evidence was graded using GRADE (Grading of Recommendations, Assessment, Development, and Evaluation). FINDINGS: The review identified 28 relevant studies focusing on dosing, treated conditions, and outcomes. The majority of the included studies (76.2%) were of low or very low quality. Several studies with moderate-to-low-quality evidence utilized a 0.14 mg/kg dosing protocol. The findings suggest promise for the use of psilocybin in chronic pain relief, though the quality of evidence is generally low. CONCLUSIONS: The current research shows potential for psilocybin as a treatment option for chronic pain relief. However, methodological issues and a lack of high-quality evidence underscore the need for further investigations with standardized protocols. Despite these limitations, the potential for psilocybin in chronic pain management is encouraging. PROSPERO REGISTRATION NUMBER: CRD42023493823.
引用
- Jevotovsky DS, Chopra H, Pak DJ, et al. Psilocybin and chronic neuropathic pain: a systematic review. Reg Anesth Pain Med. 2025. PMID: 39106989. doi:10.1136/rapm-2024-105532
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。